NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/02/2025
Back to search
Official data from USPTO
DYRUPEG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
10
Latest update
12/03/2025
Trademark type
Word
Nice classes
5
Filing date
07/23/2025
Registration date
12/02/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/02/2025
Last transaction
12/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
24
Owner location
HYDERABAD KNOWLEDGE CITY, IN
Examiner
LAVACHE,LINDA M
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CURATEQ BIOLOGICS PRIVATE LIMITED
Representatives
Joseph G. Chu JCIP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicinal preparations for use in reducing the duration and incidence of neutropenia and febrile neutropeniareducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophilsstimulating white blood cell production; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropeniareducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophilsstimulating white blood cell production; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropeniareducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophilsstimulating white blood cell productionin the form of injectable pharmaceutical solutions; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropeniareducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophilsstimulating white blood cell productionin the form of biopharmaceutical preparations; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropeniareducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophilsstimulating white blood cell productionin the form of biopharmaceutical preparations and substancespolypeptidesproteinsmonoclonal antibodies
Publications
History of USPTO decisions and trademark events.
10 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/02/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/14/2025
PUBO
PUBLISHED FOR OPPOSITION
10/14/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/08/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/16/2025
DOCK
ASSIGNED TO EXAMINER
09/09/2025
MAFR
APPLICATION FILING RECEIPT MAILED
07/23/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/23/2025
NWAP
NEW APPLICATION ENTERED
07/23/2025
Continuous trademark protection
Get notified about every new filing that threatens DYRUPEG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.